- The Myeloma Beacon - https://myelomabeacon.org -
Panobinostat (LBH589)
By: Jessica Langholtz; Published: December 3, 2009 @ 3:29 pm | Comments Disabled
| Brand Name: | |
| Generic Name: | panobinostat |
| Code Name: | LBH589 |
| Company: | Novartis |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Panobinostat (news articles [1]), which is a potent histone deacetylase (HDAC) inhibitor, selectively targets tumor cells for cell death. In Phase 1 trials, panobinostat was highly active as a single agent treatment for several types of cancer, including multiple myeloma, Hodgkin’s lymphoma, acute myeloid leukemia, and prostate cancer. Additional clinical trials are currently underway to examine the efficacy and safety profile of panobinostat.
Clinical Trials:
For a list of clinical trials studying panobinostat for the treatment of multiple myeloma, see ClinicalTrials.gov [2].
Official Web site for panobinostat: http://www.novartisoncology.com/research-innovation/pipeline/panobinostat.jsp [3]
Article printed from The Myeloma Beacon: https://myelomabeacon.org
URL to article: https://myelomabeacon.org/resources/2009/12/03/panobinostat/
URLs in this post:
[1] news articles: https://myelomabeacon.org/tag/panobinostat/
[2] ClinicalTrials.gov: http://clinicaltrials.gov/ct2/results?term=panobinostat+myeloma
[3] http://www.novartisoncology.com/research-innovation/pipeline/panobinostat.jsp: http://www.novartisoncology.com/research-innovation/pipeline/panobinostat.jsp
Click here to print.
Copyright © The Beacon Foundation for Health. All rights reserved.